Results 121 to 130 of about 30,783 (205)

Tigecycline Susceptibility of Carbapenem Resistant Enterobacteriaceae and Acinetobacter spp. isolates from Respiratory Tract: A Tertiary Care Centre Study [PDF]

open access: yesJournal of Krishna Institute of Medical Sciences University, 2020
Background: Tigecycline is used as a last line of defence against Multidrug Resistant (MDR) strains, and increasing rates of resistance are a growing concern globally. Tigecycline resistance has been reported in various pathogens including Acinetobacter
Ashish Bajaj   +7 more
doaj  

In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens [PDF]

open access: yes, 2017
Objectives To test the activity of tigecycline combined with 16 antimicrobials in vitro against 22 Gram-positive and 55 Gram-negative clinical isolates. Methods Antibiotic interactions were determined by chequerboard and time-kill methods.
Entenza, José M.   +3 more
core  

The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells [PDF]

open access: yes, 2016
peer-reviewedBackground Thuricin CD is a two-component antimicrobial, belonging to the recently designated sactibiotic subclass of bacteriocins.
Cotter, Paul D.   +4 more
core   +1 more source

Comparative Genomic Analysis of Tigecycline Resistance Development in Clinical Acinetobacter baumannii Isolates

open access: yesInfection and Drug Resistance
Xiaoxia Li,1,* Junnian Liu,2,* Xinyu Zhang,1 Juan Li,3 Luhan Xuan,1 Sue Yuan,1 Jianglin Li,1 Yu Sun,1 Xuefei Du1 1Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of
Li X   +8 more
doaj  

Genomic insights into tigecycline non-susceptibility in Clostridioides difficile: the role of the Tet P determinant and efflux mechanisms

open access: yesBMC Microbiology
Background Clostridioides difficile infection (CDI) is a significant cause of nosocomial infections, often arising from antibiotic-induced disruption of the normal gut microbiota, enabling C. difficile proliferation.
Zijun Dang   +6 more
doaj   +1 more source

Isoniazid potentiates tigecycline to kill methicillin-resistant Staphylococcus aureus

open access: yesEmerging Microbes & Infections
Therapeutic option for treating methicillin-resistant Staphylococcus aureus (MRSA) infection is urgently required since its resistance to a broad spectrum of currently available antibiotics. Here, we report that isoniazid is able to potentiate the killing efficacy of tigecycline to MRSA.
Xuan-wei Chen   +6 more
openaire   +3 more sources

Study on collateral sensitivity of tigecycline to colistin-resistant Enterobacter cloacae complex

open access: yesMicrobiology Spectrum
The past decade has witnessed the emergence and spread of carbapenem-resistant Enterobacter cloacae complex (CRECC), presenting a significant clinical challenge and urgently demanding new treatment strategies against antimicrobial resistance (AMR).
Kaixin Yu   +11 more
doaj   +1 more source

Convergence of plasmid-mediated Colistin and Tigecycline resistance in Klebsiella pneumoniae. [PDF]

open access: yesFront Microbiol, 2023
Zhao Y   +6 more
europepmc   +1 more source

A rapid liquid chromatography-tandem mass spectrometry based method for the detection of Tet(X) resistance gene in Enterobacteriaceae

open access: yesFrontiers in Microbiology
There is a major public health threat posed by antibiotic resistance around the world. Tigecycline overcomes the resistance mechanisms of traditional tetracyclines and is often seen as the final resort in combating infections caused by bacteria resistant
Liyun Zhang   +11 more
doaj   +1 more source

Emergence of carbapenem- and tigecycline-resistant Klebsiella pneumoniae ST617

open access: yesJournal of Global Antimicrobial Resistance, 2022
Lin Sun   +7 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy